These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39182140)

  • 1. LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
    Daldegan-Bueno D; Donegan CJ; Forsyth A; Sumner RL; Murphy RJ; Menkes DB; Evans W; Hoeh N; Sundram F; Reynolds LM; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Bansal M; Muthukumaraswamy S
    Trials; 2024 Aug; 25(1):560. PubMed ID: 39182140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
    Donegan CJ; Daldegan-Bueno D; Sumner R; Menkes D; Evans W; Hoeh N; Sundram F; Reynolds L; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Forsyth A; Bansal M; Muthukumaraswamy S
    Pilot Feasibility Stud; 2023 Oct; 9(1):169. PubMed ID: 37798662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.
    Murphy RJ; Sumner RL; Evans W; Menkes D; Lambrecht I; Ponton R; Sundram F; Hoeh N; Ram S; Reynolds L; Muthukumaraswamy S
    Trials; 2021 Apr; 22(1):302. PubMed ID: 33892777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdosing Psychedelics: Current Evidence From Controlled Studies.
    Murphy RJ; Muthukumaraswamy S; de Wit H
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):500-511. PubMed ID: 38280630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
    Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
    Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
    Murphy RJ; Sumner R; Evans W; Ponton R; Ram S; Godfrey K; Forsyth A; Cavadino A; Krishnamurthy Naga V; Smith T; Hoeh NR; Menkes DB; Muthukumaraswamy S
    Biol Psychiatry; 2023 Sep; 94(6):511-521. PubMed ID: 36997080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.
    Murphy RJ; Godfrey K; Shaw AD; Muthukumaraswamy S; Sumner RL
    BMC Neurosci; 2024 Feb; 25(1):7. PubMed ID: 38317077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS
    BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LSD increases sleep duration the night after microdosing.
    Allen N; Jeremiah A; Murphy R; Sumner R; Forsyth A; Hoeh N; Menkes DB; Evans W; Muthukumaraswamy S; Sundram F; Roop P
    Transl Psychiatry; 2024 Apr; 14(1):191. PubMed ID: 38622150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
    Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
    Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.
    Wells A; Muthukumaraswamy APS; Morunga E; Evans W; Cavadino A; Bansal M; Lawrence NJ; Ashley A; Hoeh NR; Sundram F; Applebaum AJ; Parkinson H; Reynolds L
    Pilot Feasibility Stud; 2024 Feb; 10(1):29. PubMed ID: 38347582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.
    Yanakieva S; Polychroni N; Family N; Williams LTJ; Luke DP; Terhune DB
    Psychopharmacology (Berl); 2019 Apr; 236(4):1159-1170. PubMed ID: 30478716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.
    Glazer J; Murray CH; Nusslock R; Lee R; de Wit H
    Neuropsychopharmacology; 2023 Jan; 48(2):418-426. PubMed ID: 36284231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.